Showing results (201-210 of 243) with videos related to
Sort By:
Pageof 25
Future Oncology (London, England)|March 4, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumorsAlison M Schram, John J Park, Antoine Italiano, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2021
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC TrialCorinne Faivre-Finn, David Vicente, Takayasu Kurata, et al.The New England Journal of Medicine|November 21, 2017
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung CancerJean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, et al.The New England Journal of Medicine|April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Noboru Yamamoto, Nicolas Girard, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2020
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni SyndromeLaura Mezquita, Maria Jové, Ernest Nadal, et al.JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2025
Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 TrialDavid Planchard, Hye Ryun Kim, Thatthan Suksombooncharoen, et al.Oncoimmunology|May 4, 2016
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLCBenjamin Besse, Mélinda Charrier, Valérie Lapierre, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2022
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerDavid R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, et al.JCO Precision Oncology|September 14, 2020
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting <i>ALK</i> and <i>ROS1</i> Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung CancerLaura Mezquita, Aurélie Swalduz, Cécile Jovelet, et al.Pageof 25